• Building B270, Babraham Research Campus, Cambridge CB22 3AT
  • Call us on +44 (0) 1223 804075

Nemesis Bioscience Ltd announced today that it has been awarded a European Innovation Council (EIC) Accelerator grant of €2 million to advance its work in the prevention of antibiotic -resistant infections. In this highly competitive process, Nemesis was one of only 74 companies funded from many thousands of applicants. In a two-year, EIC funded programme, Nemesis

Nemesis Bioscience today announced the appointment of Dr Alastair Riddell as non-executive Chairman. The appointment is effective from the 1st July and will bring Alastair’s considerable experience into the company as it continues to rapidly grow the business around its portfolio of Nemesis Symbiotics© which inactivate antibiotic resistance in pathogenic bacteria Alastair has over 30 years